MiRNA is Uniquely Suited for Personalized Medicine Personalized medicine is gaining momentum and changing the landscape of healthcare globally. MiRNA is a novel class of genetic material discovered only at the dawn of the 21st century but has continuously made headlines in biomedical research worldwide. Distinct from DNA mutations, miRNA expression level changes during disease state and offers valuable information in detecting disease onset and monitoring disease progression and recurrence. Unlike other genetic materials, miRNA is exceptional stable and accessible in biofluids, making it an ideal candidate biomarker for non-invasive blood based test. MiRNA research has been growing exponentially worldwide with Frost and Sullivan bullishly projected that “advance in microRNA is predicting future in vitro diagnostic market”.
Harnessing the power of miRNA to transform cancer management MiRXES is a privately held life science research tool provider and miRNA diagnostic test developer headquartered in Singapore. MiRXES was founded by Professor Too Heng-Phon and three like-minded partners in 2014 with the vision of creating accurate, affordable and actionable molecular diagnostic tests to improve cancer management.
Our mission is to Advance miRNA technologies to empower translational R & D Identify novel miRNA disease biomarkers in biofluids and tissues Develop non-invasive cancer screening and diagnostic tests
Forging close ties with key partners MiRXES is a spin-off from the Bioprocessing Technology Institute of the Agency of Science Technology And Research (A*STAR) and is supported by Exploit Technologies and the National University of Singapore. MiRXES collaborates extensively with academic, clinical and industrial partners locally and globally in advancing the science and business of miRNA. MiRXES is a key partner to Singapores National Diagnostic Initiative.